Roche has launched a group-wide Operational Excellence initiative aimed at “adapting to cost structures and accelerating productivity improvements.” The initiative is scheduled for implementation during 2011 and 2012. Analysts speculate that the company will cut between $2 and $3 billion from its cost structure, which could result from eliminating part of its sales force and reducing overlap with U.S. unit Genentech. The need to reduce costs stems from pipeline setbacks, a narrower window for...